ClinicalTrials.gg
RecruitingNCT06907901Updated Oct 1, 2025

Reliability of PHAS in Postural Hyperkyphosis

An observational study in Postural Kyphosis, Spine and Assessment, Self, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 8 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Istanbul University - Cerrahpasa · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
128
Ages
8 Years to 65 Years
Sex
All
01

Study summary

This observational, cross-sectional study aims to evaluate the reliability of the Postural Habits and Awareness Scale (PHAS) in patients with postural hyperkyphosis. The PHAS is designed to assess individuals' postural awareness and habits through four subscales. A total of 128 participants diagnosed with postural hyperkyphosis will complete the PHAS and the Kyphosis-Specific Spinal Appearance Questionnaire (KSSA). Test-retest reliability will be assessed by reapplying the PHAS after two weeks. Internal consistency, test-retest reliability, and concurrent validity will be analyzed. The study aims to provide a valid and reliable tool for evaluating postural awareness in clinical practice and future rehabilitation studies.

Read the detailed description

This study is designed to assess the reliability of the Postural Habits and Awareness Scale (PHAS) in individuals diagnosed with postural hyperkyphosis. Postural hyperkyphosis is increasingly common due to sedentary lifestyles, prolonged sitting, and technological device use, leading to significant postural deviations and musculoskeletal complaints. Early detection and management of postural habits are essential to prevent long-term spinal deformities and functional limitations.

The PHAS was developed to systematically evaluate individuals' postural awareness and habits in daily life, focusing on factors that contribute to poor posture and spinal alignment. The scale assesses dimensions such as postural habits, awareness of posture-disturbing factors, positional awareness, and ergonomic considerations. However, its psychometric properties, particularly reliability in hyperkyphotic patients, have not yet been established.

This observational, cross-sectional methodological study will employ standardized psychometric methods to analyze the internal consistency and test-retest reliability of the PHAS. The scale's ability to produce stable and consistent results over time will be tested through repeated administration. Additionally, concurrent validity will be examined by comparing PHAS scores with the Kyphosis-Specific Spinal Appearance Questionnaire (KSSA), which measures patients' perception of their spinal deformity.

The findings will provide valuable insights into the scale's utility for clinical and research purposes. Establishing PHAS as a reliable tool could allow physiotherapists, ergonomists, and healthcare professionals to objectively assess postural habits and awareness, design personalized rehabilitation programs, and monitor treatment outcomes. Furthermore, the scale could be integrated into preventive strategies aimed at improving postural control and spinal health in both clinical practice and community settings.

Research Team:

Assoc. Prof. Dr. Ayşe Zengin Alpözgen (Principal Investigator) PhD. PT Kübra Kardeş (Istinye University) MSc PT Selin Uz Tunçay (Istanbul University-Cerrahpasa) MSc PT Merve Koyuncu Cenikli (Istanbul University-Cerrahpasa)

02

Conditions studied

  • Postural Kyphosis
  • Spine
  • Assessment, Self

Browse trials for

Keywords

  • Hyperkyphosis
  • Postural Habits
  • Postural Awareness
  • Psychometric Analysis
  • Spinal Deformity
  • Postural Evaluation
03

In context

Kyphosis

132 studies on the registry are indexed under Kyphosis; 31 are open to participants now.

This study's planned enrollment of 128 is above the median of 62 across 45 observational studies indexed under Kyphosis.

Browse Kyphosis studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 699 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of individuals diagnosed with postural hyperkyphosis. Participants will include patients aged 8 to 65 years who have been clinically and radiologically confirmed to have postural hyperkyphosis with a Cobb angle of 50° or higher. All participants are expected to be capable of performing daily activities independently.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 8 and 65 years
  • Diagnosed with postural hyperkyphosis (Cobb angle ≥ 50° confirmed by clinical and radiological evaluation)
  • Ability to perform daily activities independently
  • Voluntary participation and signed

Exclusion criteria

Exclusion Criteria:

  • Presence of scoliosis or other spinal deformities
  • Kyphosis due to severe osteoporosis or pathological fractures
  • Diagnosis of ankylosing spondylitis or other inflammatory spinal diseases
  • Functional limitations due to acute or chronic pain
  • Previous postural awareness training or spinal rehabilitation within the last 6 months
  • Cognitive impairment or severe psychiatric disorder preventing independent questionnaire completion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hyperkyphosis Group

    Participants diagnosed with postural hyperkyphosis completing the PHAS and KSSA for reliability analysis.

    Behavioral: PHAS Assessment

Interventions

  • BehavioralPHAS Assessment

    Participants will complete the Postural Habits and Awareness Scale (PHAS) to assess postural awareness and habits. The scale will be administered twice, two weeks apart, to evaluate reliability.

06

What researchers measure

Primary outcomes

  1. Reliability of the Postural Habits and Awareness Scale (PHAS)

    Internal consistency will be evaluated using Cronbach's Alpha. Test-retest reliability will be assessed by calculating the Intraclass Correlation Coefficient (ICC) between two PHAS administrations. The PHAS consists of 19 items, each scored on a 5-point Likert scale (total score range: 19 to 95). Higher scores indicate better postural habits and awareness. Higher ICC values indicate better reliability.

    Time frame: 2 weeks

Secondary outcomes

  1. Kyphosis-Specific Spinal Appearance Questionnaire (KSSAQ)

    The KSSAQ is a 10-item, 5-point Likert scale (range: 1 to 5 per item, total score range: 10 to 50) designed to assess patients' perception of their spinal appearance related to thoracic hyperkyphosis. Higher scores indicate worse perceived deformity and greater concern about appearance. The correlation between PHAS and KSSAQ scores will be calculated to determine concurrent validity.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Istanbul University-Cerrahpasa
    Istanbul, Istanbul, Turkey (Türkiye)
    Recruiting
    • Ayşe Zengin Alpozgen, Assoc. Prof. · Contactazengin@iuc.edu.tr · 05526830479
    • Kübra Kardeş, Asst. Prof · Sub investigator
    • Selin Uz Tunçay, Msc · Sub investigator
    • Merve Koyuncu Cenikli, Msc. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
Jun 1, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907901
Responsible party
Ayse Zengin Alpozgen (Assoc. Prof., Istanbul University - Cerrahpasa) — Principal investigator
First posted
Apr 2, 2025
Start date
Jun 1, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Oct 1, 2025

Study contacts

Kübra Kardeş, PhD
Contact
kubra.koce@istinye.edu.tr
905387115631
Ayşe Zengin Alpözgen, Assoc. Prof.
principal investigator · Istanbul University - Cerrahpasa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion